O2-1-2A multicenter retrospective study of Paclitaxel vs. Paclitaxel plus Ramucirumab for advanced gastric cancer patients

O2-1-2A multicenter retrospective study of Paclitaxel vs. Paclitaxel plus Ramucirumab for advanced gastric cancer patients

Abstract Background Ramucirumab (RAM) conferred survival benefit in patients with advanced gastric cancer (AGC) in the RAINBOW trial (HR 0.807, 95% CI: 0.678-0.962, p = 0.017). However, in the Japanese subpopulation, adding RAM showed modest overall survival (OS) benefit compared with patients in We...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2019-10, Vol.30 (Supplement_6)
Hauptverfasser: Imazeki, Hiroshi, Sakamoto, Takeshi, Nakano, Michitaka, Negoro, Yuji, Yamaga, Satoru, Kawakami, Kentaro, Nishikawa, Kazuo, Izawa, Naoki, Boku, Narikazu, Tsuda, Masahiro, Esaki, Taito, Makiyama, Akitaka, Okuda, Hiroyuki, Tsuda, Takashi, Minashi, Keiko, Hironaka, Shuichi
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_6
container_start_page
container_title Annals of oncology
container_volume 30
creator Imazeki, Hiroshi
Sakamoto, Takeshi
Nakano, Michitaka
Negoro, Yuji
Yamaga, Satoru
Kawakami, Kentaro
Nishikawa, Kazuo
Izawa, Naoki
Boku, Narikazu
Tsuda, Masahiro
Esaki, Taito
Makiyama, Akitaka
Okuda, Hiroyuki
Tsuda, Takashi
Minashi, Keiko
Hironaka, Shuichi
description Abstract Background Ramucirumab (RAM) conferred survival benefit in patients with advanced gastric cancer (AGC) in the RAINBOW trial (HR 0.807, 95% CI: 0.678-0.962, p = 0.017). However, in the Japanese subpopulation, adding RAM showed modest overall survival (OS) benefit compared with patients in Western country (HR 0.88 vs. 0.73). The objective of this retrospective study was to clarify additional benefit of RAM in clinical practice for Japanese patients. Method We reviewed medical records of AGC patients who were treated with Paclitaxel (PTX) or PTX+RAM between Jan 2014 and Dec 2016 as second-line treatment in 9 Japanese institutions, excluding patients with prior use of taxane or RAM. Result A total of 154 patients were included (63 in PTX and 91 in PTX+RAM). Patient characteristics of PTX vs. PTX+RAM groups were: age (median) 64 vs. 64, male 67% vs. 75%, PS (0/1/2) 27/63/10% vs. 30/67/3%, disease status (metastatic/recurrent) 75/25% vs. 63/37%, histology (intestinal/diffuse/other) 24/57/19% vs. 31/44/25%, number of metastatic sites (0-2/≥3) 75/25% vs. 70/30%, ascites (+/-) 54/46% vs. 50/50%, and platinum combined with fluoropyrimidine in the first line (oxaliplatin/cisplatin) 16/84% vs. 37/63%. The median OS in the PTX vs. PTX+RAM groups were 7.0 vs. 9.3 months (HR 0.73, 95% CI: 0.52-1.04, p = 0.083). The median PFS were 3.2 vs. 4.1 months (HR 0.66, 95% CI: 0.47-0.93, p = 0.016). Among 39/55 patients who had measurable lesions, response rate and disease control rate were 18% vs. 35% and 56% vs. 76%, respectively. The proportion of patients receiving subsequent treatment was 57% in PTX group and 59% in PTX+RAM group. Grade 3 or more adverse events were observed more frequently in PTX+RAM group, including neutropenia (55% vs. 21%) and leucopenia (31% vs. 19%) than PTX group. Conclusion Although this study was retrospective investigation with small sample size, adding RAM to PTX conferred clinically meaningful efficacy and safety in clinical practice for Japanese patients.
doi_str_mv 10.1093/annonc/mdz339.013
format Article
fullrecord <record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdz339_013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdz339.013</oup_id><sourcerecordid>10.1093/annonc/mdz339.013</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdz339_0133</originalsourceid><addsrcrecordid>eNqVz8tKAzEYBeAgCo6XB3D3P4CZJpO2mqWI4q4i7sNvJiOR3MhlsH16W-rCravDgQOHj5AbznrOpFhgCDHohR93QsiecXFCOr5aS3rPlvyUdEwOgt6txPKcXJTyxRhby0F2ZLcZKKfDA_jmqtUmVJMhm5pjSUZXOxsotY1biBO8ona24rdxMJf-b02uFXhD37TNzeMHTDEDjjMGbUb4xFKz1aAPNUPCavc_5YqcTeiKuf7NS3L7_PT--EJjSypl6zFvFWfq4FNHnzr61N4n_jn_AcL7XNk</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>O2-1-2A multicenter retrospective study of Paclitaxel vs. Paclitaxel plus Ramucirumab for advanced gastric cancer patients</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Imazeki, Hiroshi ; Sakamoto, Takeshi ; Nakano, Michitaka ; Negoro, Yuji ; Yamaga, Satoru ; Kawakami, Kentaro ; Nishikawa, Kazuo ; Izawa, Naoki ; Boku, Narikazu ; Tsuda, Masahiro ; Esaki, Taito ; Makiyama, Akitaka ; Okuda, Hiroyuki ; Tsuda, Takashi ; Minashi, Keiko ; Hironaka, Shuichi</creator><creatorcontrib>Imazeki, Hiroshi ; Sakamoto, Takeshi ; Nakano, Michitaka ; Negoro, Yuji ; Yamaga, Satoru ; Kawakami, Kentaro ; Nishikawa, Kazuo ; Izawa, Naoki ; Boku, Narikazu ; Tsuda, Masahiro ; Esaki, Taito ; Makiyama, Akitaka ; Okuda, Hiroyuki ; Tsuda, Takashi ; Minashi, Keiko ; Hironaka, Shuichi</creatorcontrib><description>Abstract Background Ramucirumab (RAM) conferred survival benefit in patients with advanced gastric cancer (AGC) in the RAINBOW trial (HR 0.807, 95% CI: 0.678-0.962, p = 0.017). However, in the Japanese subpopulation, adding RAM showed modest overall survival (OS) benefit compared with patients in Western country (HR 0.88 vs. 0.73). The objective of this retrospective study was to clarify additional benefit of RAM in clinical practice for Japanese patients. Method We reviewed medical records of AGC patients who were treated with Paclitaxel (PTX) or PTX+RAM between Jan 2014 and Dec 2016 as second-line treatment in 9 Japanese institutions, excluding patients with prior use of taxane or RAM. Result A total of 154 patients were included (63 in PTX and 91 in PTX+RAM). Patient characteristics of PTX vs. PTX+RAM groups were: age (median) 64 vs. 64, male 67% vs. 75%, PS (0/1/2) 27/63/10% vs. 30/67/3%, disease status (metastatic/recurrent) 75/25% vs. 63/37%, histology (intestinal/diffuse/other) 24/57/19% vs. 31/44/25%, number of metastatic sites (0-2/≥3) 75/25% vs. 70/30%, ascites (+/-) 54/46% vs. 50/50%, and platinum combined with fluoropyrimidine in the first line (oxaliplatin/cisplatin) 16/84% vs. 37/63%. The median OS in the PTX vs. PTX+RAM groups were 7.0 vs. 9.3 months (HR 0.73, 95% CI: 0.52-1.04, p = 0.083). The median PFS were 3.2 vs. 4.1 months (HR 0.66, 95% CI: 0.47-0.93, p = 0.016). Among 39/55 patients who had measurable lesions, response rate and disease control rate were 18% vs. 35% and 56% vs. 76%, respectively. The proportion of patients receiving subsequent treatment was 57% in PTX group and 59% in PTX+RAM group. Grade 3 or more adverse events were observed more frequently in PTX+RAM group, including neutropenia (55% vs. 21%) and leucopenia (31% vs. 19%) than PTX group. Conclusion Although this study was retrospective investigation with small sample size, adding RAM to PTX conferred clinically meaningful efficacy and safety in clinical practice for Japanese patients.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdz339.013</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2019-10, Vol.30 (Supplement_6)</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Imazeki, Hiroshi</creatorcontrib><creatorcontrib>Sakamoto, Takeshi</creatorcontrib><creatorcontrib>Nakano, Michitaka</creatorcontrib><creatorcontrib>Negoro, Yuji</creatorcontrib><creatorcontrib>Yamaga, Satoru</creatorcontrib><creatorcontrib>Kawakami, Kentaro</creatorcontrib><creatorcontrib>Nishikawa, Kazuo</creatorcontrib><creatorcontrib>Izawa, Naoki</creatorcontrib><creatorcontrib>Boku, Narikazu</creatorcontrib><creatorcontrib>Tsuda, Masahiro</creatorcontrib><creatorcontrib>Esaki, Taito</creatorcontrib><creatorcontrib>Makiyama, Akitaka</creatorcontrib><creatorcontrib>Okuda, Hiroyuki</creatorcontrib><creatorcontrib>Tsuda, Takashi</creatorcontrib><creatorcontrib>Minashi, Keiko</creatorcontrib><creatorcontrib>Hironaka, Shuichi</creatorcontrib><title>O2-1-2A multicenter retrospective study of Paclitaxel vs. Paclitaxel plus Ramucirumab for advanced gastric cancer patients</title><title>Annals of oncology</title><description>Abstract Background Ramucirumab (RAM) conferred survival benefit in patients with advanced gastric cancer (AGC) in the RAINBOW trial (HR 0.807, 95% CI: 0.678-0.962, p = 0.017). However, in the Japanese subpopulation, adding RAM showed modest overall survival (OS) benefit compared with patients in Western country (HR 0.88 vs. 0.73). The objective of this retrospective study was to clarify additional benefit of RAM in clinical practice for Japanese patients. Method We reviewed medical records of AGC patients who were treated with Paclitaxel (PTX) or PTX+RAM between Jan 2014 and Dec 2016 as second-line treatment in 9 Japanese institutions, excluding patients with prior use of taxane or RAM. Result A total of 154 patients were included (63 in PTX and 91 in PTX+RAM). Patient characteristics of PTX vs. PTX+RAM groups were: age (median) 64 vs. 64, male 67% vs. 75%, PS (0/1/2) 27/63/10% vs. 30/67/3%, disease status (metastatic/recurrent) 75/25% vs. 63/37%, histology (intestinal/diffuse/other) 24/57/19% vs. 31/44/25%, number of metastatic sites (0-2/≥3) 75/25% vs. 70/30%, ascites (+/-) 54/46% vs. 50/50%, and platinum combined with fluoropyrimidine in the first line (oxaliplatin/cisplatin) 16/84% vs. 37/63%. The median OS in the PTX vs. PTX+RAM groups were 7.0 vs. 9.3 months (HR 0.73, 95% CI: 0.52-1.04, p = 0.083). The median PFS were 3.2 vs. 4.1 months (HR 0.66, 95% CI: 0.47-0.93, p = 0.016). Among 39/55 patients who had measurable lesions, response rate and disease control rate were 18% vs. 35% and 56% vs. 76%, respectively. The proportion of patients receiving subsequent treatment was 57% in PTX group and 59% in PTX+RAM group. Grade 3 or more adverse events were observed more frequently in PTX+RAM group, including neutropenia (55% vs. 21%) and leucopenia (31% vs. 19%) than PTX group. Conclusion Although this study was retrospective investigation with small sample size, adding RAM to PTX conferred clinically meaningful efficacy and safety in clinical practice for Japanese patients.</description><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVz8tKAzEYBeAgCo6XB3D3P4CZJpO2mqWI4q4i7sNvJiOR3MhlsH16W-rCravDgQOHj5AbznrOpFhgCDHohR93QsiecXFCOr5aS3rPlvyUdEwOgt6txPKcXJTyxRhby0F2ZLcZKKfDA_jmqtUmVJMhm5pjSUZXOxsotY1biBO8ona24rdxMJf-b02uFXhD37TNzeMHTDEDjjMGbUb4xFKz1aAPNUPCavc_5YqcTeiKuf7NS3L7_PT--EJjSypl6zFvFWfq4FNHnzr61N4n_jn_AcL7XNk</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Imazeki, Hiroshi</creator><creator>Sakamoto, Takeshi</creator><creator>Nakano, Michitaka</creator><creator>Negoro, Yuji</creator><creator>Yamaga, Satoru</creator><creator>Kawakami, Kentaro</creator><creator>Nishikawa, Kazuo</creator><creator>Izawa, Naoki</creator><creator>Boku, Narikazu</creator><creator>Tsuda, Masahiro</creator><creator>Esaki, Taito</creator><creator>Makiyama, Akitaka</creator><creator>Okuda, Hiroyuki</creator><creator>Tsuda, Takashi</creator><creator>Minashi, Keiko</creator><creator>Hironaka, Shuichi</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20191001</creationdate><title>O2-1-2A multicenter retrospective study of Paclitaxel vs. Paclitaxel plus Ramucirumab for advanced gastric cancer patients</title><author>Imazeki, Hiroshi ; Sakamoto, Takeshi ; Nakano, Michitaka ; Negoro, Yuji ; Yamaga, Satoru ; Kawakami, Kentaro ; Nishikawa, Kazuo ; Izawa, Naoki ; Boku, Narikazu ; Tsuda, Masahiro ; Esaki, Taito ; Makiyama, Akitaka ; Okuda, Hiroyuki ; Tsuda, Takashi ; Minashi, Keiko ; Hironaka, Shuichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdz339_0133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Imazeki, Hiroshi</creatorcontrib><creatorcontrib>Sakamoto, Takeshi</creatorcontrib><creatorcontrib>Nakano, Michitaka</creatorcontrib><creatorcontrib>Negoro, Yuji</creatorcontrib><creatorcontrib>Yamaga, Satoru</creatorcontrib><creatorcontrib>Kawakami, Kentaro</creatorcontrib><creatorcontrib>Nishikawa, Kazuo</creatorcontrib><creatorcontrib>Izawa, Naoki</creatorcontrib><creatorcontrib>Boku, Narikazu</creatorcontrib><creatorcontrib>Tsuda, Masahiro</creatorcontrib><creatorcontrib>Esaki, Taito</creatorcontrib><creatorcontrib>Makiyama, Akitaka</creatorcontrib><creatorcontrib>Okuda, Hiroyuki</creatorcontrib><creatorcontrib>Tsuda, Takashi</creatorcontrib><creatorcontrib>Minashi, Keiko</creatorcontrib><creatorcontrib>Hironaka, Shuichi</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Imazeki, Hiroshi</au><au>Sakamoto, Takeshi</au><au>Nakano, Michitaka</au><au>Negoro, Yuji</au><au>Yamaga, Satoru</au><au>Kawakami, Kentaro</au><au>Nishikawa, Kazuo</au><au>Izawa, Naoki</au><au>Boku, Narikazu</au><au>Tsuda, Masahiro</au><au>Esaki, Taito</au><au>Makiyama, Akitaka</au><au>Okuda, Hiroyuki</au><au>Tsuda, Takashi</au><au>Minashi, Keiko</au><au>Hironaka, Shuichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>O2-1-2A multicenter retrospective study of Paclitaxel vs. Paclitaxel plus Ramucirumab for advanced gastric cancer patients</atitle><jtitle>Annals of oncology</jtitle><date>2019-10-01</date><risdate>2019</risdate><volume>30</volume><issue>Supplement_6</issue><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Abstract Background Ramucirumab (RAM) conferred survival benefit in patients with advanced gastric cancer (AGC) in the RAINBOW trial (HR 0.807, 95% CI: 0.678-0.962, p = 0.017). However, in the Japanese subpopulation, adding RAM showed modest overall survival (OS) benefit compared with patients in Western country (HR 0.88 vs. 0.73). The objective of this retrospective study was to clarify additional benefit of RAM in clinical practice for Japanese patients. Method We reviewed medical records of AGC patients who were treated with Paclitaxel (PTX) or PTX+RAM between Jan 2014 and Dec 2016 as second-line treatment in 9 Japanese institutions, excluding patients with prior use of taxane or RAM. Result A total of 154 patients were included (63 in PTX and 91 in PTX+RAM). Patient characteristics of PTX vs. PTX+RAM groups were: age (median) 64 vs. 64, male 67% vs. 75%, PS (0/1/2) 27/63/10% vs. 30/67/3%, disease status (metastatic/recurrent) 75/25% vs. 63/37%, histology (intestinal/diffuse/other) 24/57/19% vs. 31/44/25%, number of metastatic sites (0-2/≥3) 75/25% vs. 70/30%, ascites (+/-) 54/46% vs. 50/50%, and platinum combined with fluoropyrimidine in the first line (oxaliplatin/cisplatin) 16/84% vs. 37/63%. The median OS in the PTX vs. PTX+RAM groups were 7.0 vs. 9.3 months (HR 0.73, 95% CI: 0.52-1.04, p = 0.083). The median PFS were 3.2 vs. 4.1 months (HR 0.66, 95% CI: 0.47-0.93, p = 0.016). Among 39/55 patients who had measurable lesions, response rate and disease control rate were 18% vs. 35% and 56% vs. 76%, respectively. The proportion of patients receiving subsequent treatment was 57% in PTX group and 59% in PTX+RAM group. Grade 3 or more adverse events were observed more frequently in PTX+RAM group, including neutropenia (55% vs. 21%) and leucopenia (31% vs. 19%) than PTX group. Conclusion Although this study was retrospective investigation with small sample size, adding RAM to PTX conferred clinically meaningful efficacy and safety in clinical practice for Japanese patients.</abstract><pub>Oxford University Press</pub><doi>10.1093/annonc/mdz339.013</doi></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2019-10, Vol.30 (Supplement_6)
issn 0923-7534
1569-8041
language eng
recordid cdi_oup_primary_10_1093_annonc_mdz339_013
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title O2-1-2A multicenter retrospective study of Paclitaxel vs. Paclitaxel plus Ramucirumab for advanced gastric cancer patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T06%3A02%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=O2-1-2A%20multicenter%20retrospective%20study%20of%20Paclitaxel%20vs.%20Paclitaxel%20plus%20Ramucirumab%20for%20advanced%20gastric%20cancer%20patients&rft.jtitle=Annals%20of%20oncology&rft.au=Imazeki,%20Hiroshi&rft.date=2019-10-01&rft.volume=30&rft.issue=Supplement_6&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdz339.013&rft_dat=%3Coup%3E10.1093/annonc/mdz339.013%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdz339.013&rfr_iscdi=true